董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sharon Barbari | 女 | Director | 69 | 7.66万美元 | 未持股 | 2023-11-13 |
| David Domzalski | 男 | President, Chief Executive Officer and Director | 56 | 129.35万美元 | 未持股 | 2023-11-13 |
| Steven Basta | 男 | Director | 58 | 4.41万美元 | 未持股 | 2023-11-13 |
| Elisabeth Sandoval | 女 | Director | 61 | 6.91万美元 | 未持股 | 2023-11-13 |
| Anthony Bruno | 男 | Director | 67 | 6.16万美元 | 未持股 | 2023-11-13 |
| Patrick LePore | 男 | Lead Independent Director | 68 | 8.41万美元 | 未持股 | 2023-11-13 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Domzalski | 男 | President, Chief Executive Officer and Director | 56 | 129.35万美元 | 未持股 | 2023-11-13 |
| Mutya Harsch | 女 | General Counsel, Chief Legal Officer and Secretary | 48 | 65.44万美元 | 未持股 | 2023-11-13 |
| Iain Stuart | 男 | Chief Scientific Officer | 50 | 65.39万美元 | 未持股 | 2023-11-13 |
| Tyler Zeronda | 男 | Chief Financial Officer and Treasurer | 38 | 未披露 | 未持股 | 2023-11-13 |
董事简历
中英对照 | 中文 | 英文- Sharon Barbari
-
Sharon Barbari，2009年7月起， 她担任Cytokinetics Inc.的财政执行副总裁和首席财务官。2004年9月至2009年6月，她担任财政高级副总裁和首席财务官。2002年9月至2004年8月，她担任生物医疗公司InterMune, Inc.的首席财务官和财政与行政高级副总裁。1998年1月至2002年6月，她就职于生物医疗公司Gilead Sciences, Inc.， 曾担任多职，包括最近的副总裁和首席财务官。1996至1998年，她担任旧金山国际广告与营销公司Foote, Cone & Belding Healthcare的战略规划副总裁；1972至1995年，就职于Syntex Corporation，担任公司财政、财务规划、营销和商业规划部门多个管理职位。她在圣何塞州立大学（San Jose State University）获得会计学学士学位。她在财政领域工作超过35年，曾担任多家公司的首席财务官。
Sharon Barbari,has served on Vyne Therapeutics Inc. Board since March 9, 2020, the closing date of the merger between VYNE Therapeutics Inc. (formerly Menlo Therapeutics Inc.) and Foamix Pharmaceuticals Ltd. (the "Closing Date"), and previously served as a director of Foamix from January 2019 until the Closing Date. Ms. Barbari previously served as Chief Financial Officer at Cytokinetics from 2004 to 2017 and as CFO at Gilead Sciences, where she served in senior financial roles from 1998 to 2002. Ms. Barbari also served as CFO and Senior Vice President of Finance and Administration at InterMune, and Vice President of Strategic Planning at Foote, Cone & Belding Healthcare. From 1972 to 1990, Ms. Barbari served in various roles of increasing responsibility at Syntex Corporation/Roche Pharmaceuticals. Ms. Barbari currently serves on the board of directors of Agile Therapeutics and the Association of Bioscience Finance Officers. She previously served on the board of directors of Sonoma Pharmaceuticals and for Phytogen Life Sciences. In 2017, Ms. Barbari was a recipient of the YWCA Silicon Valley Tribute to Women Awards. She received her BS in accounting from San Jose State University. - Sharon Barbari，2009年7月起， 她担任Cytokinetics Inc.的财政执行副总裁和首席财务官。2004年9月至2009年6月，她担任财政高级副总裁和首席财务官。2002年9月至2004年8月，她担任生物医疗公司InterMune, Inc.的首席财务官和财政与行政高级副总裁。1998年1月至2002年6月，她就职于生物医疗公司Gilead Sciences, Inc.， 曾担任多职，包括最近的副总裁和首席财务官。1996至1998年，她担任旧金山国际广告与营销公司Foote, Cone & Belding Healthcare的战略规划副总裁；1972至1995年，就职于Syntex Corporation，担任公司财政、财务规划、营销和商业规划部门多个管理职位。她在圣何塞州立大学（San Jose State University）获得会计学学士学位。她在财政领域工作超过35年，曾担任多家公司的首席财务官。
- Sharon Barbari,has served on Vyne Therapeutics Inc. Board since March 9, 2020, the closing date of the merger between VYNE Therapeutics Inc. (formerly Menlo Therapeutics Inc.) and Foamix Pharmaceuticals Ltd. (the "Closing Date"), and previously served as a director of Foamix from January 2019 until the Closing Date. Ms. Barbari previously served as Chief Financial Officer at Cytokinetics from 2004 to 2017 and as CFO at Gilead Sciences, where she served in senior financial roles from 1998 to 2002. Ms. Barbari also served as CFO and Senior Vice President of Finance and Administration at InterMune, and Vice President of Strategic Planning at Foote, Cone & Belding Healthcare. From 1972 to 1990, Ms. Barbari served in various roles of increasing responsibility at Syntex Corporation/Roche Pharmaceuticals. Ms. Barbari currently serves on the board of directors of Agile Therapeutics and the Association of Bioscience Finance Officers. She previously served on the board of directors of Sonoma Pharmaceuticals and for Phytogen Life Sciences. In 2017, Ms. Barbari was a recipient of the YWCA Silicon Valley Tribute to Women Awards. She received her BS in accounting from San Jose State University.
- David Domzalski
-
David Domzalski担任Vyne Therapeutics Inc.美国子公司Foamix Pharmaceuticals Inc.的总裁，自2014年4月以来在此工作。他拥有20年的工业经验，之前持有LEO Pharma Inc.销售和营销的副总裁的职位（从2009年到2013年7月），Azur Pharma的高级副总裁兼总经理（从2008年到2009年），Warner Chilcott销售和营销的副总裁（从2003年到2008年）。他拥有宾夕法尼亚州艾伦镇的默兰伯格学院（Muhlenberg College）的经济学和政治学学士学位。
David Domzalski,has served as the Company's President and Chief Executive Officer and as a director since the Closing Date. From July 2017 until the Closing Date, Mr. Domzalski served as the Chief Executive Officer of Foamix. He also served as a director of Foamix beginning in January 2018. Mr. Domzalski's tenure with Foamix began in April 2014 when he served as President of its U.S. subsidiary. Prior to that, Mr. Domzalski was the Vice President of Sales and Marketing at LEO Pharma Inc. from 2009 to 2013. Mr. Domzalski holds a B.A. in economics and political science from Muhlenberg College in Allentown, Pennsylvania. - David Domzalski担任Vyne Therapeutics Inc.美国子公司Foamix Pharmaceuticals Inc.的总裁，自2014年4月以来在此工作。他拥有20年的工业经验，之前持有LEO Pharma Inc.销售和营销的副总裁的职位（从2009年到2013年7月），Azur Pharma的高级副总裁兼总经理（从2008年到2009年），Warner Chilcott销售和营销的副总裁（从2003年到2008年）。他拥有宾夕法尼亚州艾伦镇的默兰伯格学院（Muhlenberg College）的经济学和政治学学士学位。
- David Domzalski,has served as the Company's President and Chief Executive Officer and as a director since the Closing Date. From July 2017 until the Closing Date, Mr. Domzalski served as the Chief Executive Officer of Foamix. He also served as a director of Foamix beginning in January 2018. Mr. Domzalski's tenure with Foamix began in April 2014 when he served as President of its U.S. subsidiary. Prior to that, Mr. Domzalski was the Vice President of Sales and Marketing at LEO Pharma Inc. from 2009 to 2013. Mr. Domzalski holds a B.A. in economics and political science from Muhlenberg College in Allentown, Pennsylvania.
- Steven Basta
-
Steven Basta，他曾担任Menlo Therapeutics Inc.的董事。自2015年9月起担任Menlo Therapeutics Inc.的总裁兼首席执行官。自2015年9月起担任董事会成员。他目前是Mahana Therapeutics（一家私人数字治疗公司）的首席执行官，并自2020年12月起担任该职位。从2011年10月到2015年8月，他担任AlterG（一家私人医疗设备公司）的首席执行官。从2002年11月到2010年2月，他担任BioForm Medical（被Merz收购的上市医疗美学公司）的首席执行官；从2010年2月到2011年9月，他担任Merz aesthetics （BioForm Medical的继任者）的首席执行官。他目前是上市公司Viveve Medical的董事会成员（2018年9月以来），并担任Viveve的董事会主席（2019年1月以来）。2009年9月至2016年11月担任Carbylan Therapeutics董事会成员，当时该公司被KalVista Pharmaceuticals收购。2013年12月至2015年8月，他担任RF Surgical（被美敦力收购）的董事会成员。他持有The Johns Hopkins University的学士学位和The Kellogg Graduate School of Management at Northwestern University的工商管理硕士学位。
Steven Basta,served as Vyne Therapeutics Inc. President and Chief Executive Officer from September 2015 until the Closing Date and has served as a member of Vyne Therapeutics Inc. Board since September 2015. Mr. Basta has served as the Chief Executive Officer of SaNOtize Research and Development Corp. since September 2023. From December 2020 until October 2022, Mr. Basta served as the Chief Executive Officer of Mahana Therapeutics, a privately-held digital therapeutics company. From October 2011 until August 2015, Mr. Basta served as Chief Executive Officer of AlterG, a privately held medical device company. From November 2002 to February 2010, Mr. Basta served as Chief Executive Officer of BioForm Medical, a publicly listed medical aesthetics company acquired by Merz, and from February 2010 to September 2011 served as Chief Executive Officer of Merz Aesthetics, the successor to BioForm Medical. He has served on the board of DermBiont, Inc., a privately held pharmaceutical company, since March 2020. Mr. Basta previously served as a board member of Viveve Medical from September 2018 until March 2023, including as Chairman of the Board from January 2019 until March 2023. Mr. Basta also previously served on the board of Carbylan Therapeutics from September 2009 to November 2016 when it was acquired by KalVista Pharmaceuticals. Mr. Basta served on the board of RF Surgical (acquired by Medtronic) from December 2013 to August 2015. Mr. Basta received a B.A. from The Johns Hopkins University and an M.B.A. from the Kellogg Graduate School of Management at Northwestern University. - Steven Basta，他曾担任Menlo Therapeutics Inc.的董事。自2015年9月起担任Menlo Therapeutics Inc.的总裁兼首席执行官。自2015年9月起担任董事会成员。他目前是Mahana Therapeutics（一家私人数字治疗公司）的首席执行官，并自2020年12月起担任该职位。从2011年10月到2015年8月，他担任AlterG（一家私人医疗设备公司）的首席执行官。从2002年11月到2010年2月，他担任BioForm Medical（被Merz收购的上市医疗美学公司）的首席执行官；从2010年2月到2011年9月，他担任Merz aesthetics （BioForm Medical的继任者）的首席执行官。他目前是上市公司Viveve Medical的董事会成员（2018年9月以来），并担任Viveve的董事会主席（2019年1月以来）。2009年9月至2016年11月担任Carbylan Therapeutics董事会成员，当时该公司被KalVista Pharmaceuticals收购。2013年12月至2015年8月，他担任RF Surgical（被美敦力收购）的董事会成员。他持有The Johns Hopkins University的学士学位和The Kellogg Graduate School of Management at Northwestern University的工商管理硕士学位。
- Steven Basta,served as Vyne Therapeutics Inc. President and Chief Executive Officer from September 2015 until the Closing Date and has served as a member of Vyne Therapeutics Inc. Board since September 2015. Mr. Basta has served as the Chief Executive Officer of SaNOtize Research and Development Corp. since September 2023. From December 2020 until October 2022, Mr. Basta served as the Chief Executive Officer of Mahana Therapeutics, a privately-held digital therapeutics company. From October 2011 until August 2015, Mr. Basta served as Chief Executive Officer of AlterG, a privately held medical device company. From November 2002 to February 2010, Mr. Basta served as Chief Executive Officer of BioForm Medical, a publicly listed medical aesthetics company acquired by Merz, and from February 2010 to September 2011 served as Chief Executive Officer of Merz Aesthetics, the successor to BioForm Medical. He has served on the board of DermBiont, Inc., a privately held pharmaceutical company, since March 2020. Mr. Basta previously served as a board member of Viveve Medical from September 2018 until March 2023, including as Chairman of the Board from January 2019 until March 2023. Mr. Basta also previously served on the board of Carbylan Therapeutics from September 2009 to November 2016 when it was acquired by KalVista Pharmaceuticals. Mr. Basta served on the board of RF Surgical (acquired by Medtronic) from December 2013 to August 2015. Mr. Basta received a B.A. from The Johns Hopkins University and an M.B.A. from the Kellogg Graduate School of Management at Northwestern University.
- Elisabeth Sandoval
-
Elisabeth Sandoval，她曾担任Menlo Therapeutics Inc.的成员。自2019年3月起担任董事。她目前担任制药行业的顾问。从2016年9月到2019年4月，她担任Alder Biopharmaceuticals（一家上市生物制药公司）的首席商务官和企业战略执行副总裁，主要负责领导、开发和执行商业战略。她还负责开发和领导Alder的医疗事务、投资者关系、企业沟通和业务发展职能。在加入Alder之前，她曾担任Kythera Biopharmaceuticals（一家上市的生物制药公司）的首席商务官，在那里她领导商业战略和执行，直到Kythera被Allergan收购。在Kythera之前，Sandoval女士是Bausch and Lomb Surgical的营销副总裁。在此之前，她曾担任Allergan的全球营销副总裁。她还担任Alastin Skincare（一家私人控股公司）的董事会成员。Sandoval女士的职业生涯始于Johnson & Johnson的Ethicon部门的研究和开发。她持有Pepperdine University的工商管理硕士学位和the University of California, Irvine的生物学学士学位。
Elisabeth Sandoval,has served as a member of Vyne Therapeutics Inc. Board since March 2019. Ms. Sandoval currently serves as a consultant to the pharmaceutical industry. Previously, from 2016 to 2019, she served as the Chief Commercial Officer and Executive Vice President of Corporate Strategy for Alder Biopharmaceuticals, a clinical stage company focused on developing novel therapeutic antibodies for the treatment of migraine. Prior to this, Ms. Sandoval was Chief Commercial Officer for KYTHERA Biopharmaceuticals until KYTHERA's acquisition by Allergan. Before KYTHERA, Ms. Sandoval served as Vice President of Marketing for Bausch and Lomb Surgical and Vice President of Global Marketing at Allergan with responsibility for the Medical Aesthetics division. She spent 23 years at Allergan in sales and marketing leadership roles in the specialties of dermatology, neurology, and aesthetics. Ms. Sandoval began her career in research and development at Johnson & Johnson's Ethicon division. Ms. Sandoval served on the board of directors for Satsuma Pharmaceuticals and serves on the board of directors of Procept BioRobotics. She holds an MBA from Pepperdine University and a B.S. in biology from the University of California, Irvine. - Elisabeth Sandoval，她曾担任Menlo Therapeutics Inc.的成员。自2019年3月起担任董事。她目前担任制药行业的顾问。从2016年9月到2019年4月，她担任Alder Biopharmaceuticals（一家上市生物制药公司）的首席商务官和企业战略执行副总裁，主要负责领导、开发和执行商业战略。她还负责开发和领导Alder的医疗事务、投资者关系、企业沟通和业务发展职能。在加入Alder之前，她曾担任Kythera Biopharmaceuticals（一家上市的生物制药公司）的首席商务官，在那里她领导商业战略和执行，直到Kythera被Allergan收购。在Kythera之前，Sandoval女士是Bausch and Lomb Surgical的营销副总裁。在此之前，她曾担任Allergan的全球营销副总裁。她还担任Alastin Skincare（一家私人控股公司）的董事会成员。Sandoval女士的职业生涯始于Johnson & Johnson的Ethicon部门的研究和开发。她持有Pepperdine University的工商管理硕士学位和the University of California, Irvine的生物学学士学位。
- Elisabeth Sandoval,has served as a member of Vyne Therapeutics Inc. Board since March 2019. Ms. Sandoval currently serves as a consultant to the pharmaceutical industry. Previously, from 2016 to 2019, she served as the Chief Commercial Officer and Executive Vice President of Corporate Strategy for Alder Biopharmaceuticals, a clinical stage company focused on developing novel therapeutic antibodies for the treatment of migraine. Prior to this, Ms. Sandoval was Chief Commercial Officer for KYTHERA Biopharmaceuticals until KYTHERA's acquisition by Allergan. Before KYTHERA, Ms. Sandoval served as Vice President of Marketing for Bausch and Lomb Surgical and Vice President of Global Marketing at Allergan with responsibility for the Medical Aesthetics division. She spent 23 years at Allergan in sales and marketing leadership roles in the specialties of dermatology, neurology, and aesthetics. Ms. Sandoval began her career in research and development at Johnson & Johnson's Ethicon division. Ms. Sandoval served on the board of directors for Satsuma Pharmaceuticals and serves on the board of directors of Procept BioRobotics. She holds an MBA from Pepperdine University and a B.S. in biology from the University of California, Irvine.
- Anthony Bruno
-
Anthony Bruno自2018年11月起担任Foamix的董事。Bruno先生现在已经退休了。此前，他曾担任Foamix的战略顾问（从2014年到2018年8月），以及多个专注于医疗保健的投资基金（从2011年到2018年1月）。他曾任职Warner Chilcott（从2000年到2011年），最近担任执行副总裁，负责所有业务发展活动，包括产品收购和剥离以及许可协议。他还在Warner Lambert公司工作了16年，担任多个职位，并不断增加战略责任。他的法律职业生涯始于Shearman & Sterling律师事务所。他持有雪城大学（Syracuse University）政治学学士学位，以及乔治华盛顿大学法学院（The George Washington University Law School）的法学博士学位。
Anthony Bruno,has served on Vyne Therapeutics Inc. Board since the Closing Date and previously served as a director of Foamix from November 2018 until the Closing Date. Mr. Bruno is currently retired. He previously served as a strategic consultant to Foamix from 2014 until August 2018, and to various healthcare-focused investment funds from 2011 to January 2018. He was employed at Warner Chilcott from 2000 to 2011, most recently as Executive Vice President, with responsibility for all business development activities including product acquisitions and divestitures as well as licensing agreements. Mr. Bruno also spent 16 years at Warner Lambert, holding several positions of increasing strategic responsibility. Mr. Bruno began his legal career as an associate with Shearman & Sterling. Mr. Bruno holds a B.A. in Political Science from Syracuse University, and a J.D. from The George Washington University Law School. - Anthony Bruno自2018年11月起担任Foamix的董事。Bruno先生现在已经退休了。此前，他曾担任Foamix的战略顾问（从2014年到2018年8月），以及多个专注于医疗保健的投资基金（从2011年到2018年1月）。他曾任职Warner Chilcott（从2000年到2011年），最近担任执行副总裁，负责所有业务发展活动，包括产品收购和剥离以及许可协议。他还在Warner Lambert公司工作了16年，担任多个职位，并不断增加战略责任。他的法律职业生涯始于Shearman & Sterling律师事务所。他持有雪城大学（Syracuse University）政治学学士学位，以及乔治华盛顿大学法学院（The George Washington University Law School）的法学博士学位。
- Anthony Bruno,has served on Vyne Therapeutics Inc. Board since the Closing Date and previously served as a director of Foamix from November 2018 until the Closing Date. Mr. Bruno is currently retired. He previously served as a strategic consultant to Foamix from 2014 until August 2018, and to various healthcare-focused investment funds from 2011 to January 2018. He was employed at Warner Chilcott from 2000 to 2011, most recently as Executive Vice President, with responsibility for all business development activities including product acquisitions and divestitures as well as licensing agreements. Mr. Bruno also spent 16 years at Warner Lambert, holding several positions of increasing strategic responsibility. Mr. Bruno began his legal career as an associate with Shearman & Sterling. Mr. Bruno holds a B.A. in Political Science from Syracuse University, and a J.D. from The George Washington University Law School.
- Patrick LePore
-
Patrick LePore自2020年9月起担任VYNE Therapeutics Inc.的董事，并于2021年2月被任命为首席独立董事。他曾担任Par Pharmaceutical Companies, Inc.的董事长、首席执行官和总裁，直到2012年Par Pharmaceutical Companies, Inc.出售给TPG Capital的附属公司。在2015年公司被出售给远藤国际（Endo International）期间，他继续担任董事长。他的职业生涯始于霍夫曼-拉罗彻。后来，他创立了一家医疗通信公司硼乐博（硼乐博），并于1997年上市，2002年被卖给卡地纳健康公司（Cardinal Health）。LePore先生目前是Lannett Co. Inc.的董事会主席，Matinas BioPharma的副主席，Villanova University的受托人。他曾任职PharMerica和Innoviva的董事会。他在Villanova University获得学士学位，在Farleigh Dickinson University获得工商管理硕士学位。
Patrick LePore,has served on Vyne Therapeutics Inc. Board since September 2020 and was appointed as the lead independent director in February 2021. Mr. LePore previously served as Chairman, Chief Executive Officer and President of Par Pharmaceutical Companies, Inc. from September 2006 until its sale to affiliates of TPG Capital in 2012. He remained as chairman of Par Pharmaceutical through its sale to Endo International in 2015. Mr. LePore began his career with Hoffmann-LaRoche. He later founded Boron, LePore & Associates, a medical communications company, which he took public in 1997 and was eventually sold to Cardinal Health in 2002. Mr. LePore previously served as Chairman of the Board of Lannett Co. Inc and as a director of Matinas BioPharma, PharMerica and Innoviva, and previously served as a trustee of Villanova University. Mr. LePore earned a bachelor's degree from Villanova University and a Master of Business Administration from Farleigh Dickinson University. - Patrick LePore自2020年9月起担任VYNE Therapeutics Inc.的董事，并于2021年2月被任命为首席独立董事。他曾担任Par Pharmaceutical Companies, Inc.的董事长、首席执行官和总裁，直到2012年Par Pharmaceutical Companies, Inc.出售给TPG Capital的附属公司。在2015年公司被出售给远藤国际（Endo International）期间，他继续担任董事长。他的职业生涯始于霍夫曼-拉罗彻。后来，他创立了一家医疗通信公司硼乐博（硼乐博），并于1997年上市，2002年被卖给卡地纳健康公司（Cardinal Health）。LePore先生目前是Lannett Co. Inc.的董事会主席，Matinas BioPharma的副主席，Villanova University的受托人。他曾任职PharMerica和Innoviva的董事会。他在Villanova University获得学士学位，在Farleigh Dickinson University获得工商管理硕士学位。
- Patrick LePore,has served on Vyne Therapeutics Inc. Board since September 2020 and was appointed as the lead independent director in February 2021. Mr. LePore previously served as Chairman, Chief Executive Officer and President of Par Pharmaceutical Companies, Inc. from September 2006 until its sale to affiliates of TPG Capital in 2012. He remained as chairman of Par Pharmaceutical through its sale to Endo International in 2015. Mr. LePore began his career with Hoffmann-LaRoche. He later founded Boron, LePore & Associates, a medical communications company, which he took public in 1997 and was eventually sold to Cardinal Health in 2002. Mr. LePore previously served as Chairman of the Board of Lannett Co. Inc and as a director of Matinas BioPharma, PharMerica and Innoviva, and previously served as a trustee of Villanova University. Mr. LePore earned a bachelor's degree from Villanova University and a Master of Business Administration from Farleigh Dickinson University.
高管简历
中英对照 | 中文 | 英文- David Domzalski
David Domzalski担任Vyne Therapeutics Inc.美国子公司Foamix Pharmaceuticals Inc.的总裁，自2014年4月以来在此工作。他拥有20年的工业经验，之前持有LEO Pharma Inc.销售和营销的副总裁的职位（从2009年到2013年7月），Azur Pharma的高级副总裁兼总经理（从2008年到2009年），Warner Chilcott销售和营销的副总裁（从2003年到2008年）。他拥有宾夕法尼亚州艾伦镇的默兰伯格学院（Muhlenberg College）的经济学和政治学学士学位。
David Domzalski,has served as the Company's President and Chief Executive Officer and as a director since the Closing Date. From July 2017 until the Closing Date, Mr. Domzalski served as the Chief Executive Officer of Foamix. He also served as a director of Foamix beginning in January 2018. Mr. Domzalski's tenure with Foamix began in April 2014 when he served as President of its U.S. subsidiary. Prior to that, Mr. Domzalski was the Vice President of Sales and Marketing at LEO Pharma Inc. from 2009 to 2013. Mr. Domzalski holds a B.A. in economics and political science from Muhlenberg College in Allentown, Pennsylvania.- David Domzalski担任Vyne Therapeutics Inc.美国子公司Foamix Pharmaceuticals Inc.的总裁，自2014年4月以来在此工作。他拥有20年的工业经验，之前持有LEO Pharma Inc.销售和营销的副总裁的职位（从2009年到2013年7月），Azur Pharma的高级副总裁兼总经理（从2008年到2009年），Warner Chilcott销售和营销的副总裁（从2003年到2008年）。他拥有宾夕法尼亚州艾伦镇的默兰伯格学院（Muhlenberg College）的经济学和政治学学士学位。
- David Domzalski,has served as the Company's President and Chief Executive Officer and as a director since the Closing Date. From July 2017 until the Closing Date, Mr. Domzalski served as the Chief Executive Officer of Foamix. He also served as a director of Foamix beginning in January 2018. Mr. Domzalski's tenure with Foamix began in April 2014 when he served as President of its U.S. subsidiary. Prior to that, Mr. Domzalski was the Vice President of Sales and Marketing at LEO Pharma Inc. from 2009 to 2013. Mr. Domzalski holds a B.A. in economics and political science from Muhlenberg College in Allentown, Pennsylvania.
- Mutya Harsch
Mutya Harsch是VYNE Therapeutics Inc.的首席法律官、总法律顾问和秘书。从2019年1月到截止日期，Harsch女士担任Foamix的总法律顾问和首席法律官。她此前曾担任Foamix的总法律顾问和法律事务高级副总裁（2018年1月至2019年1月）。她拥有超过20年的法律经验，此前曾担任Cooley LLP的并购特别法律顾问（2015年至2017年），以及Davis Polk & Wardwell的企业律师（2005年至2015年）。她获得了the University of California at Berkeley的法学博士和文学士学位。
Mutya Harsch,has served as the Company's Chief Legal Officer, General Counsel and Secretary since the Closing Date. From January 2019 until the Closing Date, Ms. Harsch served as the General Counsel and Chief Legal Officer of Foamix. She previously served as Foamix's General Counsel and Senior Vice President of Legal Affairs from January 2018 to January 2019. In addition, Ms. Harsch served on the board of directors of Satsuma Pharmaceuticals Inc. from October 2021 until June 2023. Ms. Harsch has over 20 years of legal experience, previously holding positions as Special Counsel, Mergers & Acquisitions at Cooley LLP from 2015 to 2017 and as a corporate lawyer at Davis Polk & Wardwell from 2005 to 2015. Ms. Harsch received her J.D. and B.A. from the University of California at Berkeley.- Mutya Harsch是VYNE Therapeutics Inc.的首席法律官、总法律顾问和秘书。从2019年1月到截止日期，Harsch女士担任Foamix的总法律顾问和首席法律官。她此前曾担任Foamix的总法律顾问和法律事务高级副总裁（2018年1月至2019年1月）。她拥有超过20年的法律经验，此前曾担任Cooley LLP的并购特别法律顾问（2015年至2017年），以及Davis Polk & Wardwell的企业律师（2005年至2015年）。她获得了the University of California at Berkeley的法学博士和文学士学位。
- Mutya Harsch,has served as the Company's Chief Legal Officer, General Counsel and Secretary since the Closing Date. From January 2019 until the Closing Date, Ms. Harsch served as the General Counsel and Chief Legal Officer of Foamix. She previously served as Foamix's General Counsel and Senior Vice President of Legal Affairs from January 2018 to January 2019. In addition, Ms. Harsch served on the board of directors of Satsuma Pharmaceuticals Inc. from October 2021 until June 2023. Ms. Harsch has over 20 years of legal experience, previously holding positions as Special Counsel, Mergers & Acquisitions at Cooley LLP from 2015 to 2017 and as a corporate lawyer at Davis Polk & Wardwell from 2005 to 2015. Ms. Harsch received her J.D. and B.A. from the University of California at Berkeley.
- Iain Stuart
Iain Stuart博士是VYNE Therapeutics Inc.的首席科学官。从2019年1月到截止日期，Stuart博士担任Foamix的首席科学官。Stuart博士此前曾担任Foamix的研发高级副总裁（2017年8月至2019年1月），以及临床开发副总裁（2016年10月至2017年）。加入Foamix之前，从2008年到2016年，他在LEO Pharma, Inc.担任多个职位，包括医疗战略和科学事务副总裁。Stuart博士持有苏格兰格拉斯哥喀里多尼亚大学（Glasgow Caledonian University）的博士学位。
Iain Stuart,has served as the Company's Chief Scientific Officer since the Closing Date. From January 2019 until the Closing Date, Dr. Stuart served as the Chief Scientific Officer of Foamix. Dr. Stuart previously served as Foamix's Senior Vice President of Research & Development from August 2017 to January 2019 and as Vice President of Clinical Development from October 2016 to 2017. Prior to joining Foamix, Dr. Stuart held several positions, including Vice President of Medical Strategy and Scientific Affairs, at LEO Pharma, Inc. from 2008 to 2016. Dr. Stuart holds a Ph.D. from Glasgow Caledonian University in Scotland.- Iain Stuart博士是VYNE Therapeutics Inc.的首席科学官。从2019年1月到截止日期，Stuart博士担任Foamix的首席科学官。Stuart博士此前曾担任Foamix的研发高级副总裁（2017年8月至2019年1月），以及临床开发副总裁（2016年10月至2017年）。加入Foamix之前，从2008年到2016年，他在LEO Pharma, Inc.担任多个职位，包括医疗战略和科学事务副总裁。Stuart博士持有苏格兰格拉斯哥喀里多尼亚大学（Glasgow Caledonian University）的博士学位。
- Iain Stuart,has served as the Company's Chief Scientific Officer since the Closing Date. From January 2019 until the Closing Date, Dr. Stuart served as the Chief Scientific Officer of Foamix. Dr. Stuart previously served as Foamix's Senior Vice President of Research & Development from August 2017 to January 2019 and as Vice President of Clinical Development from October 2016 to 2017. Prior to joining Foamix, Dr. Stuart held several positions, including Vice President of Medical Strategy and Scientific Affairs, at LEO Pharma, Inc. from 2008 to 2016. Dr. Stuart holds a Ph.D. from Glasgow Caledonian University in Scotland.
- Tyler Zeronda
Tyler Zeronda于2022年3月被任命为公司首席财务官兼财务主管，此前自2021年6月起担任临时首席财务官兼财务主管。Zeronda先生此前曾担任公司的财务副总裁，从关闭之日起直到他被任命为临时CFO。Zeronda先生于2019年4月加入Foamix，负责与VYNE的商业运营，财务规划，财务，风险管理和供应链事务相关的所有财务活动。从2013年4月至2019年4月，Zeronda先生在纳斯达克上市公司Aerie Pharmaceuticals Inc."Aerie”；担任越来越多的财务职务，最终担任财务总监。在Aerie任职期间，Zeronda先生支持公司的IPO，并帮助领导他的部门’；的成长和转型，从一个IPO前、开发阶段的实体转变为一个支持多种药物上市的完全集成的商业金融组织。加入Aerie公司之前，他曾任职Ernst&Young公司，在那里他曾专注于医疗保健行业的保证服务。Zeronda先生在弗吉尼亚大学获得会计学硕士学位，在拉斐特学院获得经济学和商业文学学士学位，并且是一名注册会计师。
Tyler Zeronda,was appointed as the Company's Chief Financial Officer and Treasurer in March 2022 and previously served as Interim Chief Financial Officer and Treasurer since June 2021. Mr. Zeronda previously served as Vice President of Finance of the Company from the Closing Date until his appointment as Interim CFO. Mr. Zeronda joined Foamix in April 2019 and has been responsible for all finance activities related to the commercial operations, financial planning, treasury, risk management and supply chain matters of VYNE. From April 2013 until April 2019, Mr. Zeronda held positions of increasing responsibility in finance at Aerie Pharmaceuticals Inc., culminating in his role as Director of Finance. Prior to joining Aerie, Mr. Zeronda was employed at Ernst & Young, LLP where he focused on assurance services in the healthcare industry. Mr. Zeronda received his M.S. in accounting from the University of Virginia holds a B.A. from Lafayette College and is a licensed CPA.- Tyler Zeronda于2022年3月被任命为公司首席财务官兼财务主管，此前自2021年6月起担任临时首席财务官兼财务主管。Zeronda先生此前曾担任公司的财务副总裁，从关闭之日起直到他被任命为临时CFO。Zeronda先生于2019年4月加入Foamix，负责与VYNE的商业运营，财务规划，财务，风险管理和供应链事务相关的所有财务活动。从2013年4月至2019年4月，Zeronda先生在纳斯达克上市公司Aerie Pharmaceuticals Inc."Aerie”；担任越来越多的财务职务，最终担任财务总监。在Aerie任职期间，Zeronda先生支持公司的IPO，并帮助领导他的部门’；的成长和转型，从一个IPO前、开发阶段的实体转变为一个支持多种药物上市的完全集成的商业金融组织。加入Aerie公司之前，他曾任职Ernst&Young公司，在那里他曾专注于医疗保健行业的保证服务。Zeronda先生在弗吉尼亚大学获得会计学硕士学位，在拉斐特学院获得经济学和商业文学学士学位，并且是一名注册会计师。
- Tyler Zeronda,was appointed as the Company's Chief Financial Officer and Treasurer in March 2022 and previously served as Interim Chief Financial Officer and Treasurer since June 2021. Mr. Zeronda previously served as Vice President of Finance of the Company from the Closing Date until his appointment as Interim CFO. Mr. Zeronda joined Foamix in April 2019 and has been responsible for all finance activities related to the commercial operations, financial planning, treasury, risk management and supply chain matters of VYNE. From April 2013 until April 2019, Mr. Zeronda held positions of increasing responsibility in finance at Aerie Pharmaceuticals Inc., culminating in his role as Director of Finance. Prior to joining Aerie, Mr. Zeronda was employed at Ernst & Young, LLP where he focused on assurance services in the healthcare industry. Mr. Zeronda received his M.S. in accounting from the University of Virginia holds a B.A. from Lafayette College and is a licensed CPA.